Registration Now Open for Leading Conference on Structural Heart Disease

NEW YORK – April 4, 2024 – The Cardiovascular Research Foundation^® (CRF^®) is excited to introduce New York Valves: The Structural Heart Summit, the expanded next iteration of our renowned annual Transcatheter Valve Therapy (TVT^®) conference. Taking place June 5-7, 2024, at the Jacob K. Javits Convention Center, North in New York City, the new summit will be a world-class educational experience in the field of structural heart interventions.

“New York Valves 2024 signifies an important milestone for our organization,” said Juan F. Granada, MD, President and Chief Executive Officer of CRF^® and New York Valves Program Director. “For the first time, this meeting will provide a unique interactive environment for networking, collaboration, and education, including all members of the heart team. It offers practitioners an unprecedented opportunity to learn about the latest developments in each specific area of our field. Through real multi-specialty collaboration, this summit will not only advance our knowledge but also directly impact patient care worldwide."

For nearly two decades, CRF^® has led the way in pioneering transcatheter therapies for structural heart disease at TVT^®. New York Valves marks the next iteration of this legacy, featuring three days of transformative research and techniques that will redefine the landscape of structural heart interventions. It’s the premier gathering uniting interventional cardiologists, cardiac surgeons, clinical cardiologists, cardiac imagers, heart failure experts, and other members of the heart team under one roof. With a renewed emphasis on multidisciplinary collaboration, New York Valves offers attendees the opportunity to harness the collective expertise of all specialties to develop the most effective and personalized treatment strategies for patients with valvular and structural heart disease.

“New York Valves 2024 is more than just a meeting; it's a multidisciplinary movement reshaping the landscape of cardiovascular care in patients with valvular and structural heart disease,” said Martin B. Leon, MD, Founder and Chairman Emeritus of CRF^® and New York Valves Program Director. “From novel therapies to best clinical practices, this summit embodies the evolution of transcatheter and surgical interventions. Our goal is to unite specialists from every corner of cardiovascular care to extend the heart team, redefine innovations, and develop new standards for managing valve patients."

Transcatheter valve therapy has evolved from a novel treatment for the sickest patients to become the standard of care for many with aortic stenosis. The rapid adoption of transcatheter mitral and tricuspid therapies has also transformed the treatment landscape, expanding options for patients with structural heart disease.

New York Valves 2024 will showcase advanced techniques and evidence-based medicine through live-case demonstrations, hands-on training, lively debate, and the latest updates that contribute knowledge to the field. With a distinguished lineup of world-renowned experts, this comprehensive program is designed as a practical, case-based course that will delve into best practices, clinical decision-making, patient selection, and strategies for devices, imaging, procedures, and complications management. The summit will also feature the latest breakthroughs and research in the field providing attendees with an unparalleled opportunity to explore the newest techniques and technologies in structural heart interventions. 

About CRF® 

The Cardiovascular Research Foundation^® (CRF^®) is a global leader in interventional cardiovascular medicine, driving innovation, spearheading groundbreaking research, and transforming education in the field. Through its relentless pursuit of excellence, CRF^® not only accelerates medical breakthroughs but also equips healthcare professionals with the tools and knowledge necessary to enhance survival rates and elevate the quality of life for millions worldwide. CRF’s centers of excellence include the CRF Skirball Center for Innovation, CRF Clinical Trials Center, CRF Center for Education, CRF Digital, TCTMD, and Structural Heart: The Journal of the Heart Team. For more information, visit www.crf.org.

###

Premier Meeting for Pioneering Data and Updates on Heart Failure Treatments Will Take Place March 4-6 in Boston

WHAT:

The complete list of late-breaking clinical science to be presented at THT 2024: Technology and Heart Failure Therapeutics is now available online. An international heart failure conference organized by the Cardiovascular Research Foundation® (CRF®), THT will take place March 4-6, 2024, at the Westin Boston Seaport in Boston, MA. The full program guide can be found at https://tht2024.crfconnect.com/program-guide.

Now in its third year, THT 2024 has evolved into the premier destination for groundbreaking data and updates on heart failure treatments. This unique conference offers a dynamic platform to explore the intersection of device- and technology-based treatments within the broader context of drug therapies. THT shines a spotlight on fostering synergy between traditional and innovative approaches to heart failure management. Three sessions will feature 20 late-breaking clinical science presentations focusing on transcatheter approaches to treating a diverse range of heart failure patients.

Featured Late-Breaking Clinical Science Abstracts I

Tuesday, March 5, 2024

2:00 PM — 3:17 PM EST

Grand Ballroom A-B, Concourse Level

 

One Year Outcomes of Left Atrial to Coronary Sinus Shunting for Treatment of Symptomatic Heart Failure; The ALT FLOW Early Feasibility Study One Year Results

Firas Zahr

The Pivotal ALIVE Trial of the Revivent TC Transcatheter Ventricular Enhancement System in Heart Failure Patients with Prior Anterior Myocardial Infarction

Jerry D. Estep

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Randomized Trial 12-Month Results

Sanjiv J. Shah

Initial Experience with Transcatheter Myotomy (SESAME) to Treat Hypertrophic Cardiomyopathy and Left Ventricular Outflow Obstruction

Adam B. Greenbaum

Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices (DOAC LVAD) Study

Palak Shah

Cardiac Pulmonary Nerve Stimulation Improves Outcomes of Patients with Acute Decompensated Heart Failure: Results of the STOP-ADHF Pilot Study

Sitaramesh Emani

An International Multicenter Report on Long Term Outcomes after LVAD Explantation - The VAD Wean Registry

Snehal R. Patel

 

Featured Late-Breaking Clinical Science Abstracts II

Tuesday, March 5, 2024

4:30 PM — 5:47 PM EST

Grand Ballroom A-B, Concourse Level

 

RECOVER-HF Pilot Study: Synchronized Diaphragmatic Stimulation for HFrEF Therapy

Marat Fudim

Relationship of Patient Adherence to the Performance of a Remote Speech Analysis System to Detect Worsening Heart Failure Events in Ambulatory Heart Failure Patients

William T. Abraham

A Nationwide Study of a Remote Patient Monitoring and Intervention Program: The Impact on Heart Failure Clinical Outcomes and Healthcare Cost

David Ian Feldman

Derivation and Validation of a Multicenter Model to Identify Candidates for Advanced HF Therapies with High Potential to Achieve post-LVAD Reverse Cardiac Remodeling

Stavros G. Drakos

Short-term Atrial Shunt Device-Induced Changes in Cardiac Structure/Function and Risk of Subsequent Heart Failure Events: Findings from the REDUCE-LAP HF II Randomized Clinical Trial

David M. Kaye

Remote Management of Sitting Pulmonary Artery Pressures Tested Against a Performance Goal of Reduced HF Hospitalizations and All-cause Mortality in a Prospective Multi-Center Open Label PROACTIVE-HF Trial in NYHA Class III Heart Failure

Liviu Klein

 

Featured Late-Breaking Clinical Science Abstracts III

Wednesday, March 6, 2024

8:00 AM — 9:15 AM EST

Grand Ballroom C-E, Concourse Level

 

A Novel Cardiac Scale and Algorithm for Detecting Worsening Congestion Preceding Heart Failure Events (HFEs): A Preliminary Analysis of the SCALE-HF 1 Study

Marat Fudim

Serial Direct Sodium Removal in Patients with Heart Failure and Diuretic Resistance

Jeffrey Testani

Aquapheresis for Management of Decompensated Heart Failure: A Re-appraisal of AVOID-HF

Sean P. Pinney

AI Assisted Identification of Super Responders for Ultrafiltration can Reduce 90-Day Readmission Rates: Evidence from AVOID-HF Trial

Deya Alkhatib

Multicenter Development and Validation of a Supervised Machine Learning Risk Model to Predict Right Ventricular Failure Following Mechanical Circulatory Support: The STOP-RVF Score

Stavros G. Drakos

Introduction Of Guideline Directed Medical Therapy And Native Heart Recovery In Patients Supported By Impella 5.5

Kanika P. Mody

Impact Of Rapid Up-Titration of Guideline-Directed Medical Therapies On Quality of Life: Insights From The STRONG-HF Trial

Kamile Cerlinskaite-Bajore

Additional information on THT is available at https://tht2024.crfconnect.com/.

WHY:

Approximately 6.7 million adults in the United States have heart failure. The incidence of heart failure is projected to increase by 46% from 2012 to 2030, affecting more than 8 million people.

Given the growing prevalence of heart failure and innovation in new therapies, CRF recognizes the importance of creating a high-quality research and educational conference featuring new diagnostic approaches and advanced technologies to treat various forms of heart failure.

WHEN:         

March 4-6, 2024

WHERE:

Westin Boston Seaport District

425 Summer Street

Boston, MA 02210

WHO:

The program directors for THT 2023 are:

 

Daniel Burkhoff, MD, PhD

Cardiovascular Research Foundation

New York, NY

 

Jerry D. Estep, MD

Cleveland Clinic Florida

Weston, FL

 

Ulrich P. Jorde, MD

Montefiore Medical Center

Bronx, NY

 

Manreet Kanwar, MD

Allegheny General Hospital

Pittsburgh, PA

 

Navin K. Kapur, MD

Tufts Medical Center

Boston, MA

 

Martin B. Leon, MD

NewYork-Presbyterian/Columbia University Irving Medical Center

New York, NY

 

JoAnn Lindenfeld, MD

Vanderbilt Heart and Vascular Institute

Nashville, TN

 

Steven O. Marx, MD

NewYork-Presbyterian/Columbia University Irving Medical Center

New York, NY

 

Gabriel Sayer, MD

NewYork-Presbyterian/Columbia University Irving Medical Center

New York, NY

 

W. H. Wilson Tang, MD

Cleveland Clinic

Cleveland, OH

 

Nir Uriel, MD

NewYork-Presbyterian/Columbia University Irving Medical Center

New York, NY

 

HOW TO REGISTER:

Media may apply for registration by emailing jromero@crf.org.

Annual Scientific Symposium of CRF^® Will Take Place October 27-30, 2024, in Washington, DC

WHAT:

Media registration is now open for TCT^® 2024 (Transcatheter Cardiovascular Therapeutics^®), the annual scientific symposium of the Cardiovascular Research Foundation^® (CRF^®). TCT^® is the world’s premier educational meeting specializing in interventional cardiovascular medicine and will be held October 27-30, 2024, in Washington, DC, at the Walter E. Washington Convention Center.

Each year, TCT^® unveils medical breakthroughs and brings together top researchers and clinicians worldwide to present and deliberate on the most recent evidence-based research in the field. The conference showcases late-breaking clinical trials and science, live case transmissions from various corners of the globe, poster and oral abstracts, challenging cases, innovation sessions, and unlimited opportunities for learning and global collaboration. It is a four-day, comprehensive, practical, and interactive experience led by world-renowned experts in coronary, structural, and endovascular interventions. This year, TCT^® will embrace a comprehensive approach with a focus on integrating preventive measures alongside interventional to proactively combat and mitigate cardiovascular disease.

WHEN:

October 27-30, 2024

WHERE:

Walter E. Washington Convention Center

Washington, DC

WHY:

Heart disease is the leading cause of death worldwide. Every year, the discoveries made through hundreds of studies and late-breaking trials presented at TCT® lead to advancements in new medicines and devices that ultimately improves the care and quality of life for people with heart disease.

HOW TO REGISTER:

Media may register for in-person or online press access at https://tct2024.crfconferences.com/press-registration.

A New Annual Ranking of Global Academic and Medical Institutions Based on Academic Contribution at TCT 2023

NEW YORK – November 20, 2023 – The Cardiovascular Research Foundation (CRF), in conjunction with the Transcatheter Cardiovascular Therapeutics (TCT) 2023 conference, CRF's annual scientific symposium, announced today the launch of the CRF Scientific Excellence Top 10 (SET-10), a new global annual ranking recognizing academic contributions to interventional cardiovascular medicine.

The SET-10 initiative, aligning with CRF's commitment to advancing the field, aims to recognize and celebrate the extraordinary contributions made by medical and academic institutions globally in interventional cardiovascular research.

Thirty-two esteemed institutions earned the SET-10 distinction, with the top ten institutions recognized globally for their dedication to advancing scientific knowledge in interventional cardiovascular medicine. The new ranking span six categories, acknowledging excellence within and outside the United States, underscoring the far-reaching impact of these institutions on the field.

The rankings are based on a rigorous evaluation of all scientific submissions for TCT 2023, with expert reviewers assessing submissions from the United States, outside the United States, structural, and coronary categories. The rankings were determined through a statistical formula including the quality and quantity of the submissions submitted. Further details on the methodology of the SET-10 initiative, and the complete list of rankings and categories can be found here.

Juan F. Granada, MD, President and CEO of CRF and TCT Program Director, expressed enthusiasm: "We're thrilled to acknowledge and celebrate these outstanding academic and medical institutions for their innovative research showcased at TCT. This cutting-edge research enriches the global pool of knowledge in interventional cardiovascular medicine, significantly influencing patient care and the approach to treating heart disease by physicians. The critical research conducted at institutions worldwide showcased in the CRF SET-10 rankings helps propel new advances and practical treatments for patients.”